The FDA has approved Eli Lilly’s imlunestrant, an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed following at least one prior endocrine therapy. The approval is based on results from a phase 3 trial, which included 874 patients. Among 256 […] The post FDA approves breast cancer drug appeared first on Becker's Hospital Review | Healthcare News & Analysis.
